Francis Chou
Chou Associates Management
Chou Associates Management Portfolio 13F
Francis Chou Holdings Activity
- Portfolio value:
- $323.79M≈ (+$22M≈)
- Previous value:
- $301.42M≈
- # of changes:
- 4
- New positions:
- 0
- Reported for:
- 30 Jun 2017 (Q2)
- Latest filing date:
- 15 Aug 2017
Chou Associates Management has disclosed a total of 4 changes to the portfolio in the (2017 Q2) SEC report(s): increased the number of shares of 2 and decreased the number of shares of 2 position(s).
What did Francis Chou invest in during 2017 Q2?
In the 2017 Q2 report(s) the following change has been made to the top investments: (VRX) Valeant Pharmaceuticals International Inc (added shares +29.74%).
4 results
| History | Ticker | Name |
% or activity |
Shares change |
Shares held after* |
% change to portfolio |
Reported price* |
% difference current price* |
% of portfolio |
Held since* | Held for* |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Teva Pharma Industries Ltd ADR
|
+134.88%
|
$33.34
|
-7.17%($30.96)
|
5.20%
|
2017 Q1
|
≈ 0.50 years
|
||||
|
|
Valeant Pharmaceuticals International Inc
|
+29.74%
|
$17.37
|
|
16.38%
|
2016 Q1
|
≈ 1.50 years
|
||||
|
|
Citigroup Inc
|
-24.39%
|
$67.13
|
+96.70%($132.05)
|
6.43%
|
2013 Q2 or earlier
|
≈ 4.25+ years
|
||||
|
|
Nokia Corp ADR
|
-54.55%
|
$6.18
|
+48.87%($9.20)
|
2.39%
|
2013 Q2 or earlier
|
≈ 4.25+ years
|
||||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
* Current price: this can be a delayed price and may not reflect the real-time market value, however it is too close.
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* Held since / Held for: calculated since the latest "new buy" position. If the security was previously exited and re-entered, only the most recent holding period is counted.